Association of stem cell marker expression pattern and survival in human biliary tract cancer

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 511-522

  Kemmerling, Ralf ^a   Alinger, Beate ^a   Dietze, Otto ^a   Bösmüller, Hans Christian ^c   Ocker, Matthias ^b   Wolkersdörfer, Gernot W ^a   Berr, Frieder ^a   Neureiter, Daniel ^a   Kiesslich, Tobias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

Human biliary tract cancer; Prognosis; Stem cell marker; Xenografts

Indexed keywords

BETA CATENIN; BMI1 PROTEIN; CD133 ANTIGEN; CD44V ANTIGEN; CELL CYCLE PROTEIN; CYTOKERATIN 7; CYTOKERATIN 8; KI 67 ANTIGEN; MESSENGER RNA; NESTIN; PROTEIN P27; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UVOMORULIN;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR LOCALIZATION; XENOTRANSPLANTATION;

AGED; ANIMALS; ANTIGENS, DIFFERENTIATION; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863604908     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1477     Document Type: Article

References (57)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med 341: 1368-1378, 1999.
2. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I and Molinari M: Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208: 134-147, 2009.
3. Zografos GN, Farfaras A, Zagouri F, Chrysikos D and Karaliotas K: Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int 10: 10-20, 2011.
4. Kiesslich T, Wolkersdorfer G, Neureiter D, Salmhofer H and Berr F: Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci 8: 23-30, 2009.
5. Verslype C, Prenen H and Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10: 164-167, 2008. (Pubitemid 352016240)
6. Bailey JM, Singh PK and Hollingsworth MA: Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 102: 829-839, 2007. (Pubitemid 350036923)
7. Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H and Alpini G: Molecular pathology of biliary tract cancers. Cancer Lett 250: 155-167, 2007. (Pubitemid 46529440)
8. Wiedmann MW and Mossner J: Molecular targeted therapy of biliary tract cancer - results of the first clinical studies. Curr Drug Targets 11: 834-850, 2010.
9. Neureiter D, Herold C and Ocker M: Gastrointestinal cancer - only a deregulation of stem cell differentiation? (Review). Int J Mol Med: 483-489, 2006.
10. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749, 2005. (Pubitemid 41486367)
11. Brabletz S, Schmalhofer O and Brabletz T: Gastrointestinal stem cells in development and cancer. J Pathol 217: 307-317, 2009.
12. Jopling C, Boue S and Izpisua Belmonte JC: Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol 12: 79-89, 2011.
13. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
14. Todaro M, Francipane MG, Medema JP and Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162, 2010.
15. Alison MR, Lim SM and Nicholson LJ: Cancer stem cells: problems for therapy? J Pathol 223: 147-161, 2011.
16. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27: 844-850, 2009.
17. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902, 2010.
18. Wang M, Xiao J, Shen M, et al: Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer 128: 72-81, 2011.
19. Nagai K, Ishii H, Miyoshi N, et al: Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. Biochem Biophys Res Commun 395: 258-263, 2010.
20. Kiesslich T, Alinger B, Wolkersdorfer GW, Ocker M, Neureiter D and Berr F: Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol 36: 49-58, 2010.
21. Berman DM, Karhadkar SS, Maitra A, et al: Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846-851, 2003. (Pubitemid 37351469)
22. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W and Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313: 856-862, 2004. (Pubitemid 38050071)
23. Neureiter D, Zopf S, Dimmler A, et al: Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology 5: 387-397, 2005. (Pubitemid 41160276)
24. Zopf S, Neureiter D, Bouralexis S, et al: Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 31: 1391-1402, 2007.
25. Kemmerling R, Stintzing S, Muhlmann J, Dietze O and Neureiter D: Primary testicular lymphoma: A strictly homogeneous hematological disease? Oncol Rep 23: 1261-1267, 2010.
26. Tannapfel A and Wittekind C: The current TNM system for gastrointestinal tumors part II. Pathologe 31: 348-352, 2010 (In German).
27. Malhi H and Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867, 2006. (Pubitemid 44646688)
28. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
29. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902, 2010.
30. Zhang C, Fu X, Chen P, et al: Dedifferentiation derived cells exhibit phenotypic and functional characteristics of epidermal stem cells. J Cell Mol Med 14: 1135-1145, 2010.
31. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
32. Sasaki M, Yamaguchi J, Ikeda H, Itatsu K and Nakanuma Y: Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies. Hum Pathol 40: 1723-1730, 2009.
33. Horst D, Kriegl L, Engel J, Jung A and Kirchner T: CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45: 2034-2040, 2009.
34. Miller G, Socci ND, Dhall D, et al: Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 28: 62, 2009.
35. Jarnagin WR, Klimstra DS, Hezel M, et al: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24: 1152-1160, 2006. (Pubitemid 46638813)
36. Karamitopoulou E, Tornillo L, Zlobec I, et al: Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 130: 780-786, 2008.
37. Ohtsubo I, Ajiki T, Hori Y, et al: Distinctive expression of CD133 between intraductal papillary neoplasms of the bile duct and bile duct adenocarcinomas. Hepatol Res: Jan 6, 2012 (Epub ahead of print).
38. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
39. Kiesslich T, Berr F, Alinger B, Kemmerling R, Pichler M, Ocker M and Neureiter D: Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol: May 24, 2011 (Epub ahead of print).
40. Dalerba P, Dylla SJ, Park IK, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163, 2007. (Pubitemid 47175279)
41. Quint K, Stintzing S, Alinger B, et al: The expression pattern of PDX-1, SHH, patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 9: 116-126, 2009.
42. Li L and Clevers H: Coexistence of quiescent and active adult stem cells in mammals. Science 327: 542-545, 2010.
43. Scoville DH, Sato T, He XC and Li L: Current view: intestinal stem cells and signaling. Gastroenterology 134: 849-864, 2008. (Pubitemid 351312767)
44. Gillet JP, Calcagno AM, Varma S, et al: Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108: 18708-18713, 2011.
45. Kiesslich T and Neureiter D: Editorial: Advances in targeting the hedgehog signaling pathwy in cancer therapy. Expert Opin Ther Targets 16: 151-156, 2012.
46. Matsuoka J, Yashiro M, Sakurai K, et al: Role of the stemness factors Sox2, Oct3/4, and Nanog in gastric carcinoma. J Surg Res: 130-135, 2012.
47. Zhang X, Yu H, Yang Y, et al: SOX2 in gastric carcinoma, but not Hath1, is related to patients' clinicopathological features and prognosis. J Gastrointest Surg 14: 1220-1226, 2010.
48. Lin T, Ding YQ and Li JM: Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol: Feb 20, 2011 (Epub ahead of print).
49. Liu JH, Song LB, Zhang X, et al: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 97: 267-272, 2008. (Pubitemid 351312168)
50. Saiki Y, Ishimaru S, Mimori K, et al: Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol 16: 2638-2644, 2009.
51. Wang H, Pan K, Zhang HK, et al: Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541, 2008. (Pubitemid 351422607)
52. Wang Q, He W, Lu C, et al: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 29: 1233-1241, 2009.
53. Lengerke C, Fehm T, Kurth R, et al: Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 11: 42, 2011.
54. Vrzalikova K, Skarda J, Ehrmann J, et al: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 134: 1037-1042, 2008.
55. Hayry V, Tynninen O, Haapasalo HK, et al: Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 34: 555-563, 2008.
56. Shi CJ, Gao J, Wang M, et al: CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol 17: 2965-2971, 2011.
57. + population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 10: 1182-1190, 2010.